Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 7, 2011

View Archived Issues

BD Diagnostics files for FDA clearance for fully automated molecular assays for herpes

New antagonists of melanin-concentrating hormone MCH1 receptor claimed

New inhibitors of FADK 1, JAK2 and JAK3 described

X-ray crystallography provides insight into formation of complement convertase

Triheptanoin has anticonvulsant effects in models of epilepsy

PanOptica raises funds to develop topical treatment for AMD

Insulin PharmFilm is tested in primates

Mercator Therapeutics and Pepscan Therapeutics join to optimize anticancer homing peptides

Almirall and Forest Labs report on aclidinium bromide trials

AnaptysBio triggers milestone payment from Merck & Co.

Bioniche Life Sciences raises funds to support several programs

Anadys begins phase IIb study of ANA-598 in hepatitis C

FDA lifts clinical hold on phase II Alferon LDO trial in influenza

Cellzome researchers describe novel ZAP-70 inhibitors

Invega approved in E.U. for schizoaffective disorder

Novel B-raf inhibitors discovered at Nerviano Medical Sciences

New ligands of transient receptor potential TRPM8 channel patented

Santarus and Depomed resume Glumetza distribution in U.S.

SuperGen enrolls first patient in phase I SGI-110 trial in MDS and AML

Omeros licenses new antifibrinolytic agents from University of California

Algeta completes enrollment into phase III Alpharadin trial

Avila Therapeutics designs irreversible and selective HCV protease inhibitors

Enrollment complete in EXPAND trial of Erbitux in gastric cancer

Cynapsus and IntelGenx sign definitive license agreement for INT-0010

Gold-bound TNF-alpha formulation CYT-6091 enters clinic

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...